Trump will sign FDA user fee reauthorization bill, ending threat of agency layoffs
Ahead of its summer recess, the US Senate today followed its House counterparts and passed a bipartisan bill to reauthorize FDA user fee programs for prescription drugs, generic drugs, medical devices and biosimilars for the next five years. A spokesman for President Donald Trump told Focus, “The President will sign this bill, but we look forward to working with Congress to address further negotiations.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters